Sutro Biopharma(STRO) - 2024 Q3 - Quarterly Report

Product Development - The company is developing site-specific and novel-format antibody drug conjugates (ADCs) using its proprietary XpressCF® and XpressCF+® platforms, targeting clinically validated cancer treatments [123]. - The most advanced product candidate, STRO-002 (luvelta), is designed for patients with FRα-expressing cancers, including ovarian cancer, and has shown promising preliminary efficacy data in Phase 1 trials [124][126]. - The company initiated a Phase 2/3 study (REFRαME-O1) in June 2023, enrolling 57 patients, with plans to randomize approximately 516 patients in Part 2 of the study [132]. - The company is also exploring luvelta in combination with bevacizumab, showing an ORR of 56% at the recommended Phase 2 dose [134]. - The IND for treating FRα-expressing non-small cell lung cancer (NSCLC) with luvelta was cleared by the FDA in early 2024, with a Phase 2 study initiated in August 2024 [137]. - The company plans to file an IND for its preclinical asset STRO-004 in the second half of 2025, targeting tissue factor with a differentiated safety profile [140]. - The company has entered into collaborations with leading pharmaceutical companies, including licensing agreements for luvelta in Greater China with Tasly, which received its first IND clearance in August 2023 [141]. Financial Performance - The company reported a net loss of $155.0 million for the nine months ended September 30, 2024, compared to a net loss of$137.9 million for the same period in 2023, reflecting an increase in losses [144]. - Total revenue for the three months ended September 30, 2024, was $8.5 million, down 50$16.9 million in the same period of 2023 [159]. - Revenue from Astellas Pharma for the three months ended September 30, 2024, was $7.7 million, a decrease of 23$10.0 million in the same period of 2023 [160]. - The accumulated deficit as of September 30, 2024, was $714.4 million, indicating significant ongoing financial challenges [144]. - Operating expenses for the three months ended September 30, 2024, totaled$76.4 million, a 25% increase from $60.9 million in the same period of 2023 [159]. - The company had a loss from operations of$67.9 million for the three months ended September 30, 2024, compared to a loss of $44.0 million in the same period of 2023, representing a 54$8.4 million to $40.0 million for the three months ended September 30, 2024, compared to the same period in 2023 [161]. - Research and development expenses increased by$16.4 million, or 36%, to $62.0 million for the three months ended September 30, 2024 [162]. - General and administrative expenses decreased by$0.9 million, or 6%, to $14.0 million for the three months ended September 30, 2024 [163]. - Total revenue increased by$7.2 million, or 18%, to $47.2 million for the nine months ended September 30, 2024, compared to the same period in 2023 [168]. - Research and development expenses increased by$54.3 million, or 43%, to $181.0 million for the nine months ended September 30, 2024 [170]. - General and administrative expenses decreased by$6.4 million, or 14%, to $39.4 million for the nine months ended September 30, 2024 [171]. Cash Flow and Financing - Cash, cash equivalents, and marketable securities totaled$388.3 million as of September 30, 2024 [176]. - The company sold 667,780 shares of Vaxcyte common stock for net proceeds of $74.0 million during the three months ended September 30, 2024 [177]. - Cash used in operating activities for the nine months ended September 30, 2024 was$119.8 million, compared to $125.7 million for the same period in 2023 [193][194]. - Cash provided by investing activities for the nine months ended September 30, 2024 was$131.0 million, primarily from maturities and sales of marketable securities of $394.5 million [195]. - Cash provided by financing activities for the nine months ended September 30, 2024 was$94.1 million, mainly from $71.5 million of net proceeds from an underwritten offering [197]. - The company had cash, cash equivalents, and marketable securities of$388.3 million as of September 30, 2024, up from $333.7 million as of December 31, 2023 [203]. - The company may seek additional financing through public or private equity offerings, debt financings, and collaborations, but adequate funding may not be available on acceptable terms [189]. Lease Obligations - The aggregate estimated base rent payments due over the San Carlos Lease Extension Period is approximately$4.2 million [184]. - The aggregate estimated base rent payments due over the Industrial Lease Extension Period is approximately $4.3 million [185]. - The total estimated base rent payments due over the Sublease term is approximately$39.1 million, including a potential financial benefit of $5.2 million in rent abatement [187]. Interest Rate and Risk Management - The company does not engage in investments for trading or speculative purposes and has not used derivative financial instruments to manage interest rate risk exposure [204]. - The company does not anticipate being exposed to material risks due to changes in interest rates [204]. - A hypothetical 10% change in market interest rates would not have a material impact on the company's financial statements [204]. - The company believes that its cash, cash equivalents, or marketable securities do not have a significant risk of default or illiquidity [204].